NIH Awards Advaita $2M for Disease Subtyping, Drug Repurposing Technology DevelopmentThe National Institute of General Medical Sciences of the National Institutes of Health issued a Notice of Award granting a Fast-Track Small Business Investigational Research Phase I and Phase II grant of $2.0 million for Advaita to develop biological pathway analysis tools for personalized medicine and drug repositioning.
More Positive Test Results For Plymouth Firm's Cholesterol DrugEsperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
'Proud To Manufacture In Michigan' Goes Up North The Plymouth-based Michigan Manufacturing Technology Center has set its "Proud to Manufacture In Michigan II" event for Sept. 18 and 19 at the Hagerty Conference Center, 715 E. Front St., on the campus of Northwestern Michgian College in Traverse City.
Comcast Unveils Another Xfinity Customer Center, This Time In Rochester HillsComcast Friday held a special reception and ribbon-cutting event to announce the grand opening of its all-new Xfinity Customer Center in Rochester Hills.
Burroughs Announces Patent Licensing Agreement with Silver BulletBurroughs Inc. said it has reached an agreement with Pensacola, Fla.-based Silver Bullet Technologies Inc. to license Burroughs' U.S. Patent No. 6,546,396 for use in Silver Bullet's Ranger and follow on software product for use with tabletop scanners.
Esperion Therapeutics Reports Financial Details, Corporate UpdateEsperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
Hawaii Police Find Remains Of Mich. Man Missing Since 2007Police in Hawaii have identified human remains found in a remote area of a volcano as belonging to a metro Detroit man reported missing nearly six years ago.
Rofin-Sinar Reports Results For The Third Quarter Of Fiscal Year 2013Rofin-Sinar Technologies Inc. (Nasdaq: RSTI), the industrial laser maker with dual headquarters in Plymouth and Hamburg, Germany, reported financial results for the third fiscal quarter and nine months ended June 30.
Michigan Pre-Seed Capital Fund Invests $1.5 Million in Six StartupsSix more Michigan companies in industries ranging from bicycles to off-grid power to high-tech health have received investments from the Michigan Pre-Seed Capital Fund, totaling $1.5 million.
Comcast Launches Xfinity Home Control In MichiganComcast, Michigan's No. 1 cable TV provider, Tuesday announced the Michigan launch of Xfinity Home Control, a new product under the Xfinity Home umbrella of services.
Automotive Style Returns With Concours d'Elegance In PlymouthThe Concours d'Elegance kicks off Sunday in Plymouth -- where beautiful, classic and exotic automobiles will be on display.
Burroughs Offers Image Software that Integrates Check and Cash Deposits into the Teller LineBurroughs Inc. Thursday announced a software distributor agreement with Sullivan, Ill.-based Jaguar Software Development Inc. to sell and distribute its MirrorImage suite of application modules which can be configured to handle different item processing environments in the financial industry.
Esperion Stock Interest Strong, Underwriters’ Over-Allotment Option ExercisedEsperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
Esperion Therapeutics Going Public (Again) At $14 A Share
Esperion Gets Positive Results From New Study Of Cholesterol DrugEsperion Therapeutics Inc. Friday announced "positive" results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.